IL-33 treatment contributes to homeostasis in the adipose tissue by facilitating the differentiation and maintenance of Foxp3+ST2+ Treg cells and ILC2 in visceral adipose tissue, an immunomodulatory effect that can contribute towards down-regulating obesity-associated inflammation [79,85]. The gene discussed is FOXP3; the disease is obesity disorder.